Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 37, 2002 - Issue 4
Submit an article Journal homepage
563
Views
347
CrossRef citations to date
0
Altmetric
Research Article

Butyrate Inhibits NF-κB Activation in Lamina Propria Macrophages of Patients with Ulcerative Colitis

H. Lührs
,
T. Gerke
,
J. G. Müller
,
R. Melcher
,
J. Schauber
,
F. Boxberger
,
W. Scheppach
&
T. Menzel
 show all
Pages 458-466 | Published online: 08 Jul 2009

  • Kirsner JB. Inflammatory bowel disease. Part I: Nature and pathogenesis. Dis Mon 1991;37:605-66.
  • Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerati v e colitis. A long-term followup of 1116 patients. Dig Dis Sci 1993;38:1137-46.
  • Gonzalez-Licea A, Yandley JH. Nature of the tissue reaction in ulcerative colitis. Light and electron microscopic findings. Gastroenterology 1966;51:825-40.
  • Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242(4878):540-6.
  • Cheng Q, Cant CA, Moll T, Hofer-Warbinek R, Wagner E, Birnstiel ML, et al. NK-kappa B subunit-specific regulation of the I kappa B alpha promoter. J Biol Chem 1994;269:13551-7.
  • Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994; 10:405-55.
  • Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996:87:13-20.
  • Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993:187:233-56.
  • Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
  • Beg AA, Finco TS, Nantermet PV, Baldwin AS, Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. MoI Cell Biol 1993;13:3301-10.
  • Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NFkappa Bl precursor protein and the activation of NF-kappa B. Cell 1994:78:773-85.
  • Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signalinduced phosphorylation. Science 1995:267(5203):1485-8.
  • Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 1995:80:573-82.
  • Beutler B, Van Huffel C. An evolutionary and functional approach to the TNF receptor/ligand family. Ann NY Acad Sci 1994:730:118-33.
  • Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992:37:818-26.
  • MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990:81:301-5.
  • Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992:102:529-37.
  • Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mo no nuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993:94:174-81.
  • Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993:104:749-58.
  • Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. MoI Cell Biol 1993:13:6231-40.
  • Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995:86:1243-54.
  • Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 1995:40;949-59.
  • Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994:55:97-179.
  • Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 1992; 176:1583-93.
  • Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-I). J Biol Chem 1992:267:16323-9.
  • Grilli M, Chiu JJ, Lenardo MJ. NF-kappaB and ReI: participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993:143:1-62.
  • Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998:115:357-69.
  • Jobin C, Hellerbrand C, Licato LL, Brenner DA, Sartor RB. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 1998:42:779-87.
  • Jobin C, Herfarth HH, Sartor RB. Dexamethasone inhibits TNFalpha gene expressio n through an I kappa B/NF kappa B pathway in intestinal IEC-6 cells. Gastroenterology 1996;110:A333.
  • Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
  • Conner EM, Brand S, Grisham MB. Inhibition of granulomatous colitis by a selective proteasome inhibitor: antagonists of nuclear transcription factor kappa B activation. Gastroenterology 1996; 110:A887.
  • Bugaut M. Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals. Comp Biochem Physiol [B] 1987:86:439-72.
  • Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonie mucosa in man. Gut 1980;21:793-8.
  • Roediger WE. The colonie epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980;2(8197):712-5.
  • Roediger WE. The starved colon-diminished mucosal nutrition, diminished absorption, and colitis. Dis Colon Rectum 1990;33: 858-62.
  • Agarwal VP, Schimmel EM. Diversion colitis: a nutritional deficiency syndrome? Nutr Rev 1989;47:257-61.
  • Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christi S, et al. Effect of butyrate enemas on the colonie mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51-6.
  • Senagore AJ, MacKeigan JM, Scheider M, Ebrom JS. Shortchain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992:35:923-7.
  • Vernia P, Marcheggiano A, Caprilli R, Frieri G, Corrao G, Val pian i D, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:309-13.
  • Breuer RI, Buto SK, Christ ML, Bean J, Vernia P, Paoluzi P, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci 1991 ;36: 185-7.
  • Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditi s with butyrate enemas. Am J Gastroenterol 1994;89:179-83.
  • Vernia P, Cittadini M, Caprilli R, Torsoli A. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995;40:305-7.
  • Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S, Braverman DZ. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol 1996;91:731-4.
  • Kripke SA, Fox AD, Berman JM, Settle RG, Rombeau JL. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN J Parenter Enterai Nutr 1989:13:109-16.
  • Kvietys PR, Granger DN. Effect of volatile fatty acids on blood flow and oxygen uptake by the dog colon. Gastroenterology 1981;80(5pt 1):962-9.
  • Mortensen FV, Nielsen H, Mulvany MJ, Hessov I. Short chain fatty acids dilate isolated human colonie resistance arteries. Gut 1990:31:1391-4.
  • D'Argenio G, Cosenza V, Sorrentini I, De Ritis F, Gatto A, Delle Cave M, et al. Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity. Gastroenterology 1994;106:399-404.
  • Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonie epithelial cell line. Gastroenterology 2000; 118:724-34.
  • Segain JP, Raingeard de la Bleuere D, Bourreille A, Leray V, Gervois N, Resales C, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403.
  • Luhrs H, Gerke T, Schauber J, Dusel G, Melcher R, Scheppach W, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis 2001;16:195-201.
  • Scheppach W. Treatment of distal ulcerative colitis with shortchain fatty acid enemas. A placebo-controlled trial. GermanAustrian SCFA Study Group. Dig Dis Sci 1996;41:2254-9.
  • Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
  • Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989:320:23-8.
  • Den Hond E, Hiele M, Evenepoel P, Peelers M, Ghoos Y, Rutgeerts P. In vivo butyrate metabolism and colonie permeability in extensive ulcerative colitis. Gastroenterology 1998; 115:584-90.
  • Gilbert KM, Weigle WO. Thl cell energy and blockade in GIa phase of the cell cycle. J Immunol 1993;151:1245-54.
  • Siavoshian S, Blottiere HM, Bentouimou N, Cherbut C, Galmiche JP. Butyrate enhances major histocompatibility complex class I, HLA-DR and ICAM-1 antigen expression on differentiated human intestinal epithelial cells. Eur J Clin Invest 1996:26:803-10.
  • Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, Zlabinger GJ. n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by shortchain fatty acids. Immunology 1997:92:234-43.
  • Jobin C, Sartor RB. The IkappaB/NF-kappaB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000;278:C451-62.
  • Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and upregulation of IL-10 production. Faseb J 2000:14:2380-2.
  • Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NFkappa B in inflamed mucosa of patients with ulcerative colitis. [In Process Citation]. Am J Gastroenterol 2000:95:3452-7.
  • Scheppach W, Muller JG, Boxberger F, Dusel G, Richter F, Bartram HP, et al. Histological changes in the colonie mucosa following irrigation with short-chain fatty acids. Eur J Gastroenterol Hepatol 1997;9:163-8.
  • Vemia P, Fracasso PL, Casale V, Villotti G, Marcheggiano A, Stigliano V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 2000:356(9237): 1232-5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.